Magazine Article | February 7, 2018

2018 NDAs: Living In The Wake Of 2017

Source: Life Science Leader

By ISR

With 46 new drugs approved in 2017 (51 if you include five biosimilars), we see that the pharma industry was quite busy. The number of new drug approvals more than doubled from 2016’s level of 22, which begs the question: What is the knock-on effect of a near-record volume of approvals? When one thinks about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities, the impact is likely substantial.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: